key: cord-0746785-v4p617qm
authors: Bouabdella, Sara; Benkaraache, Mounia; Almheirat, Yousef; Zizi, Nada; Dikhaye, Siham
title: Erythema multiforme eruption due to SARS-COV 2: Case report
date: 2021-07-26
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.102591
sha: 2a68a161b6cfb94430baf89016cb3ee0e640dda2
doc_id: 746785
cord_uid: v4p617qm

INTRODUCTION: and importance: The COVID-19 is a global pandemic that is now responsible for more than 3 million deaths around the world. Its cutaneous manifestations in patients are being increasingly reported. This case brings additional data implementing the knowledge on the dermatological signs during COVID-19. CASE PRESENTATION: We report a new pattern with erythema multiforme (EM) lesions in a healthy patient with COVID-19 infection and no other medical background. CLINICAL DISCUSSION: We are facing challenging times in Dermatology. New information and cutaneous manifestations possibly related to COVID‐19 are emerging every day. There are only a few case reports describing EM in patients with COVID-19. CONCLUSION: We suggest that this EM might be another pattern of exanthem associated with COVID‐19 infection. Further studies are needed to evaluate whether these lesions are associated with the virus, the drug intake or any other conditions.

The COVID-19 is a global pandemic that is now responsible 6 for more than 3 million deaths around the world. Its cutaneous manifestations in patients are 7 being increasingly reported. This case brings additional data implementing the knowledge on 8 the dermatological signs during COVID-19. Case presentation: We report a new pattern 9 with erythema multiforme (EM) lesions in a healthy patient with COVID-19 infection and no 10 other medical background. Since December 2019, COVID-19 has spread throughout the world at a staggering pace,  22 gradually becoming a pandemic. Although known to primarily affect the lungs and the 23 respiratory function, recent reports from around the world have brought to our attention the 24 possibility of cutaneous involvement [1] . It may present with different types of cutaneous 25 manifestations of varying pathophysiology. We report the observation a new pattern with 26 erythema multiforme (EM) lesions in a patient with COVID-19 infection. 27

Our case report was written according to CARE guidelines [2] . reported. Several patterns have been described [3] . Erythema multiforme (EM) is an acute, 50

immune-mediated disease characterized by target-like cutaneous lesions [4] . It consists of a 51 polymorphous eruption of macules, papules and characteristic 'target' lesions that are 52 symmetrically distributed with a propensity for the distal extremities [5] . suggested that the eruption might be associated with SARS-CoV-2 rather than 64 hydroxychloroquine or other infectious agents [5] . New information and details of cutaneous 65 manifestations possibly related to COVID-19 are emerging every day. Further studies are 66 needed to evaluate whether these lesions are associated with the virus, the drugs used or any 67 other conditions [3] . EM is linked to infectious agents in 90% of cases, while drug-associated 68 EM is reported in less than 10%. Herpes simplex virus and Mycoplasma pneumoniae are the 69 J o u r n a l P r e -p r o o f main agents, but other viruses have been reported, such as adenovirus, coxsackievirus and 70 parvovirus B19 [3] . 71

In our patient, the lesions might also be related to COVID-19. We also hypothesized that the 72 drugs administered to our patient might potentiate the cutaneous reaction induced by SARS-73 

Cutaneous manifestations in confirmed COVID-19 patients: A systematic review

CARE guidelines for case reports: explanation and elaboration document

Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings

A case of erythema multiforme major in a patient with COVID 19: The role of corticosteroid treatment

Atypical erythema multiforme palmar plaques lesions due to Sars-Cov-2

Acute generalized exanthematous pustulosis with erythema

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.The ethical committee approval was not required give the article type ( case report ) .However , the written consent to publish the clinical data of the patients was given and is available to check by the handling editor if needed .J o u r n a l P r e -p r o o f Consent Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors. 

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries. This is not an original research project involving human participants in an interventional or an observational study but a case report . This registration is was not required .

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish Sara Bouabdella J o u r n a l P r e -p r o o f